Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee

Arthritis committee is expected to discuss the increased risk of infections when Orencia (abatacept) is used in combination with other biologic rheumatoid arthritis therapies during the Sept. 6 review of Bristol's drug.